Bristol-Myers Squibb Company Interest Expense 2011-2026 | BMY

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Bristol-Myers Squibb Company

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-674 M	-893 M	1.16 B	-576 M	1.33 B	1.42 B	656 M	183 M	196 M	167 M	184 M	203 M	199 M	182 M	145 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.42 B	-893 M	259 M

Quarterly Interest Expense Bristol-Myers Squibb Company

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-494 M	-339 M	-234 M	-273 M	-81 M	258 M	116 M	288 M	-	299 M	313 M	326 M	-	328 M	330 M	353 M	-	346 M	357 M	362 M	-	209 M	123 M	45 M	-	44 M	45 M	46 M	-	48 M	52 M	45 M	-	42 M	42 M	43 M	-	41 M	49 M	51 M	-	50 M	46 M	54 M	-	46 M	50 M	50 M	-	48 M	41 M	42 M	-	40 M	32 M	31 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
362 M	-494 M	84.3 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Alector ALEC	13.2 M	$ 2.11	-13.17 %	$ 217 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
Apellis Pharmaceuticals APLS	-133 K	$ 20.52	-2.12 %	$ 2.59 B	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Axsome Therapeutics AXSM	-15.9 M	$ 164.13	0.15 %	$ 8.17 B	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Aytu BioScience AYTU	-512 K	$ 2.49	-3.11 %	$ 15.6 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
BridgeBio Pharma BBIO	43.1 M	$ 64.24	-3.37 %	$ 12.3 B	USA
BioAtla BCAB	6.22 M	$ 0.18	-26.92 %	$ 8.6 M	USA
BioCardia BCDA	3 K	$ 1.37	6.2 %	$ 29 M	USA
BioCryst Pharmaceuticals BCRX	59.3 M	$ 8.61	-1.66 %	$ 1.78 B	USA
Black Diamond Therapeutics BDTX	6.92 M	$ 2.4	-3.04 %	$ 132 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	-7.26 M	$ 11.47	-0.43 %	$ 742 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Biogen BIIB	268 M	$ 187.68	-2.16 %	$ 27.5 B	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
BioVie BIVI	4.3 M	$ 1.38	-0.01 %	$ 2.04 M	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 2.91	2.83 %	$ 908 M	Israel
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
BioMarin Pharmaceutical BMRN	15.3 M	$ 60.68	-1.7 %	$ 11.6 B	USA
Benitec Biopharma BNTC	-126 K	$ 10.85	-0.5 %	$ 447 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
BioXcel Therapeutics BTAI	20.2 M	$ 1.63	-2.69 %	$ 4.13 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Athira Pharma ATHA	3.96 M	-	-	$ 269 M	USA